Clinical Trials Directory

A Randomized Phase II Trial of Multi-Epitope Vaccination With Melanoma Peptides For Cytotoxic T Cells And Helper T Cells For Patients With Metastatic Melanoma

RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying four different vaccines using melanoma peptides from cytotoxic T cells and helper T cells to see how well they work in treating patients with metastatic melanoma.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • biological : incomplete Freund's adjuvant
  • biological : melanoma helper peptide vaccine
  • biological : tetanus peptide melanoma vaccine
  • biological : sargramostim
  • biological : multi-epitope melanoma peptide vaccine

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting

Footer Links: